| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/27/2001 | WO2001009178A3 Human chaperone proteins |
| 09/27/2001 | WO2001001968A3 Methods and compositions for regulating gut motility and food intake |
| 09/27/2001 | WO2000071148A3 Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin |
| 09/27/2001 | WO2000059489A8 Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites |
| 09/27/2001 | WO2000057837A8 Compositions and methods for effecting the levels of cholesterol |
| 09/27/2001 | WO2000012047A3 Enhancement of return to independent living status with a growth hormone secretagogue |
| 09/27/2001 | US20010025057 Containing nitric oxide donar containing nitroglycerin, glycol dinitrate, isopropyl nitrate, glyceryl-1,3-dinitrate, glyceryl-1,2-dinitrate, butane-1,2,4-triol-trinitrate, erythrityl teteranitrate, pentaerithrityl tetetranitrate etc. |
| 09/27/2001 | US20010025040 Useful for treating allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis; nonsedating antihistamines or salts, leukotriene D4 antagonist or 5-lipoxygenase inhibitor or FLAP protein antagonist |
| 09/27/2001 | US20010025039 Tricyclic aza-indolyl derivatives substituted with ethylamine group is useful for treating central nervous system disorder,cardiovascular disorder, gastrointestinal disorders, diabetes insipidus, and particularly useful for obesity |
| 09/27/2001 | US20010025032 Administering mixture of nucleosides; anticancer agent |
| 09/27/2001 | US20010025028 Methods of inhibiting bone resorption |
| 09/27/2001 | US20010024824 Stem cells and their use in transplantation |
| 09/27/2001 | US20010024664 Alzheimer's diseases; central nervous system disorders; antiinflammatory agent; solvent extraction from plants |
| 09/27/2001 | US20010024658 A delayed release pharmaceutical dosage form for oral administration of heparin comprising a low molecular weight heparin, a bile salt or acid, and a surfactant selected from hydrophilc and lipophilic, and a means for sustained release |
| 09/27/2001 | US20010024650 Artery - and vein-specific proteins and uses therefor |
| 09/27/2001 | DE10014516A1 Selective prevention of atherosclerosis or restenosis, comprises using RANTES CCR1 receptor antagonist to block monocyte recruitment in atherosclerotic plaque or neointima |
| 09/27/2001 | DE10012151A1 Aerosol inhalant containing vitamin A compound in liposomes based on phosphatidylcholine, useful for treatment of tracheo-bronchial illnesses, especially chronic obstructive pulmonary disease |
| 09/27/2001 | DE10010612A1 Treatment of erectile dysfunction without inducing circulatory side-effects, using penis-specific phosphodiesterase V inhibitors, preferably benzo (4,5) thieno (2,3-d) pyrimidine derivatives |
| 09/27/2001 | CA2404260A1 Identification of essential genes in prokaryotes |
| 09/27/2001 | CA2404216A1 Novel polypeptides, and nucleic acids encoding the same |
| 09/27/2001 | CA2404139A1 Binding compounds and methods for identifying binding compounds |
| 09/27/2001 | CA2404115A1 The use of peg-hirudin as an anticoagulant agent in the extracorporeal treatment of blood |
| 09/27/2001 | CA2403823A1 Thioketals and thioethers for inhibiting the expression of vcam-1 |
| 09/27/2001 | CA2403815A1 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis |
| 09/27/2001 | CA2403809A1 Angiogenesis - associated proteins, and nucleic acids encoding the same |
| 09/27/2001 | CA2403804A1 Vegf-modulated genes and methods employing them |
| 09/27/2001 | CA2403788A1 Receptor-binding compounds and methods for identifying them |
| 09/27/2001 | CA2403784A1 Binding compounds and methods for identifying binding compounds |
| 09/27/2001 | CA2403714A1 Use of substances modulating the expression or the function of a protein involved in the cell cycle for treating or preventing acute neural injuries |
| 09/27/2001 | CA2403707A1 Diphenyl ketoaldehyde derivatives with anti-hiv activity |
| 09/27/2001 | CA2403669A1 Methods and reagents for regulation of cellular responses in biological systems |
| 09/27/2001 | CA2403631A1 Spiropiperidine derivatives as melanocortin receptor agonists |
| 09/27/2001 | CA2403533A1 Methods and systems for enhancing fluid flow through an obstructed vascular site |
| 09/27/2001 | CA2403444A1 Restenosis treatment |
| 09/27/2001 | CA2403436A1 Acute neuronal induced calcium binding protein type 1 ligand |
| 09/27/2001 | CA2402763A1 Proteases |
| 09/27/2001 | CA2402747A1 G-protein associated molecules |
| 09/27/2001 | CA2402722A1 Sperm factor oscillogenin |
| 09/27/2001 | CA2402611A1 Bactericidal preparation |
| 09/27/2001 | CA2402414A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 09/27/2001 | CA2402285A1 Nimr compositions and their methods of use |
| 09/27/2001 | CA2401984A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 09/27/2001 | CA2401067A1 Methods for screening and identifying pathogen virulence factors |
| 09/27/2001 | CA2400637A1 Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma |
| 09/27/2001 | CA2399985A1 Compounds with 5-ht activity useful for controlling visual field loss |
| 09/27/2001 | CA2399695A1 Pharmaceutical composition for administration to mucosal surfaces |
| 09/27/2001 | CA2383848A1 Diagnosis of a person's risk of developing alcoholism |
| 09/26/2001 | EP1136567A1 Method and kit for the screening, the detection and /or the quantification of transcriptional factors |
| 09/26/2001 | EP1136547A2 Adamts polypeptides, nucleic acids encoding them, and uses thereof |
| 09/26/2001 | EP1136079A1 Agents for retarding change of hormone-dependent cancer into hormone-independent cancer |
| 09/26/2001 | EP1136078A2 Combination of angiotensin converting enzyme inhibitor and side- effect-reduced amount of aldosterone antagonist |
| 09/26/2001 | EP1136073A1 Compositions suitable for the treatment of damage caused by ischemia/reperfusion or oxidative stress |
| 09/26/2001 | EP1136071A2 Use of glycogen phosphorylase inhibitors |
| 09/26/2001 | EP1135688A2 Methods and compositions useful for targeting activated vitronectin receptor alpha(nu)-beta(3) |
| 09/26/2001 | EP1135677A1 In vivo biosensor apparatus and method of use |
| 09/26/2001 | EP1135535A2 Development of anti-microbial agents based on bacteriophage genomics |
| 09/26/2001 | EP1135534A1 Use of factor x polymorphism in the diagnosis and treatment of factor x and/or factor xa mediated diseases |
| 09/26/2001 | EP1135519A1 Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases |
| 09/26/2001 | EP1135513A1 Adenovirus-mediated gene therapy |
| 09/26/2001 | EP1135503A2 DRUG TARGETS IN $i(CANDIDA ALBICANS) |
| 09/26/2001 | EP1135497A1 Polypeptides capable of interacting with the human topoisomerase iii alpha |
| 09/26/2001 | EP1135496A2 Ucp5 |
| 09/26/2001 | EP1135495A2 Secreted amd transmembrane polypeptides and nucleic acids encoding the same |
| 09/26/2001 | EP1135494A2 Neuron-associated proteins |
| 09/26/2001 | EP1135491A2 Methods and compositions for inhibiting neoplastic cell growth |
| 09/26/2001 | EP1135490A1 Human vanilloid receptors and their uses |
| 09/26/2001 | EP1135489A1 Pth1r and pth3r receptors |
| 09/26/2001 | EP1135486A1 RECOMBINANT SOLUBLE Fc RECEPTORS |
| 09/26/2001 | EP1135485A2 Promotion or inhibition of angiogenesis and cardiovascularization |
| 09/26/2001 | EP1135483A2 Cytokine signal regulators |
| 09/26/2001 | EP1135482A1 Cancer cell vaccine |
| 09/26/2001 | EP1135477A1 Humanized monoclonal antibodies |
| 09/26/2001 | EP1135467A1 Psca: prostate stem cell antigen and uses thereof |
| 09/26/2001 | EP1135413A2 Proteins that bind angiogenesis-inhibiting proteins, compoisitions and methods of use thereof |
| 09/26/2001 | EP1135412A2 Tumor necrosis factor receptor homologue-1 (trh1) |
| 09/26/2001 | EP1135411A1 Methods and compositions for treating disorders involving excitotoxicity |
| 09/26/2001 | EP1135193A1 Agents provided for treating tumors, based on liposomes, and containing tamoxifen |
| 09/26/2001 | EP1135169A1 Pharmaceutical composition comprising an anti-cancer agent and at least a peptide |
| 09/26/2001 | EP1135166A1 Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 09/26/2001 | EP1135161A1 Chemotherapeutic composition and method |
| 09/26/2001 | EP1135157A1 Method for regulating the permeability of the blood brain barrier |
| 09/26/2001 | EP1135156A2 Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells |
| 09/26/2001 | EP1135153A1 Uses for eph receptor antagonists and agonists to treat vascular disorders |
| 09/26/2001 | EP1135150A1 Self-emulsifying compositions for drugs poorly soluble in water |
| 09/26/2001 | EP1135146A1 Pharmaceutical composition containing fish oil, vitamin e and c and acetylsalicyl acid against arteriosclerosis |
| 09/26/2001 | EP1135144A1 Compositions and methods for regulating bacterial pathogenesis |
| 09/26/2001 | EP1135136A1 Pharmaceutical compositions containing olanzapine-n-oxide |
| 09/26/2001 | EP1135134A1 Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases |
| 09/26/2001 | EP1135128A2 Novel method of treatment |
| 09/26/2001 | EP1135121A2 Combination of duloxetine with non-steroidal antiinflammatory drug for treating pain |
| 09/26/2001 | EP1135120A2 Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents |
| 09/26/2001 | EP1135118A1 Dispersible compositions containing l-dopa ethyl ester |
| 09/26/2001 | EP1135115A2 Use of sibutramine for the treatment of disorders of the central nervous system secondary to organic impairments |
| 09/26/2001 | EP1135105A2 Method for administering agents to the central nervous system |
| 09/26/2001 | EP0839026B1 Polyether block copolymer micellar compositions for targeting biological agents |
| 09/26/2001 | CN1314948A Targeted adenovirus vectors for delivery of heterologous genes |
| 09/26/2001 | CN1314917A Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinase |
| 09/26/2001 | CN1314913A Directed combinatorial compound library and high throughput assays for screening same |
| 09/26/2001 | CN1314912A Tartrate salt of a sabstituted dipentide as growth hormone secretagogue |
| 09/26/2001 | CN1314811A Therapies for treating pulmonary diseases |